ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Nimbus Therapeutics Logo

Nimbus Therapeutics

Erin has more than 20 years HR leadership experience across biotech, medical device, manufacturing and entertainment industries. Jean is a General Partner of Lightstone Ventures. Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Katharine Knobil has more than 20 years of experience in the pharmaceutical industry including global clinical research, medical affairs, and patient safety across both big pharma and smaller biotechnology companies. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S.

Quick overview

Cambridge, United States

Founded in 2009

11-50 Employees

Additional information

Working industry

Biotechnology

Type of company

-

Ownership structure

Privately Held

Locations

1 Headquarter

Specialised areas

Biological research Pharmaceuticals , Drugs and Druggists' Sundries Merchant Wholesalers, Scientific Research and Development Services, Health Care, Biotechnical research, commercial, Therapeutics, Biotechnology, Professional, Scientific, and Technical Services, Alternative Medicine

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Headquarter of Nimbus Therapeutics

Nimbus Therapeutics operates in 1 country around the world

City: Cambridge

State: Massachusetts

Country: United States

Locations of Nimbus Therapeutics

Get an overview of the locations of Nimbus Therapeutics

Location

Country

State

City

Headquarter

United States

Massachusetts

Cambridge

Frequently asked questions (FAQ) about Nimbus Therapeutics

Some frequent questions that have been asked about Nimbus Therapeutics

The company headquarter of Nimbus Therapeutics is located in Cambridge, Massachusetts, United States. It's worth noting, that the company may have more locations

As of the latest available information Nimbus Therapeutics has around 11-50 employees worldwide.

Nimbus Therapeutics was founded in 2009

The company Nimbus Therapeutics has it's main focus in the industries of Biotechnology

Competitors of Nimbus Therapeutics

Check out some interesting alternative companies to Nimbus Therapeutics

Receptor Life Sciences's Logo

Receptor Life Sciences

Seattle, United States

1-10 Employees

2015

Mark is a healthcare executive with more than 20 years of experience. Leone-Bay is an internationally recognized authority on inhaled dry powder and oral drug delivery technologies. Kraft has over 20 years of pharmaceutical industry experience in oral and inhaled drug delivery. Kraft leads Receptor's product development team from basic research through manufacturing, testing, release, and stability of Phase 1 clinical supplies. Weissman leads alliance management, business development, corporate communications, corporate operations, and new product planning. Weissman was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Warren Lammert has over 35 years of public and private investment experience and is the founder and Co-Chief Investment Officer of Granite Point Capital, a Boston-based investment firm with over $300 million in assets that invests in both public and private companies. Prior to Antios, Mayes founded Engage Therapeutics and served as the company’s President and CEO.

Esya's Logo

Esya

Newbury, United Kingdom

1-10 Employees

2018

We are a start-up originally spun out of Dr. Dhivya is a passionate Entrepreneur with 15+ years experience in defining winning strategies and building high performance teams. Vergara has 14+ years of experience in experimental and computational biology. Shellard has a PhD and 12+ years of experience in cell biology and live imaging. Brian brings a track record of leading teams to deliver transformative results for clients across the healthcare sector at McKinsey and Company with particular focus on strategy / corporate finance, go-to-market, and M&A. Laghrissi is the CEO of DalCor Pharmaceuticals and has more than 20 years of pharmaceutical industry leadership experience, including roles at AstraZeneca, Roche, HBA and WPIC. Kupfer is the ex-Head of the DSM-5 plan committee, and has expert knowledge of the current principal manual for psychiatric & neurocognitive diagnosis, as recommended by the American Psychiatric Association. Linder is the CEO at Calciscon AG, biomedical consultant, entrepreneur & senior biotech executive with track record of success for biomedical devices.

IO Biotech's Logo

IO Biotech

Copenhagen, Denmark

51-100 Employees

2015

Ahmad is a trained internist and clinical oncologist and brings over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise. Zocca brings more than 18 years of experience in the biotechnology field and has participated in the founding and co-founding of several biotech spinouts. Sullivan is a seasoned life sciences professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Faulkner brings more than 25 years of technical operations, quality, and product launch experience within the biotechnology industry. Faulkner has experience in product development, manufacturing operations, supply chain, and commercialization of peptides, proteins, monoclonal antibodies, viruses, and combination products. Faulkner held senior roles at Homology Medicines as head of CMC management and external manufacturing, product operations lead for the Rare Disease Business Unit at Shire (Takeda), and spent over 15 years at Biogen involved in the development and commercialization of Avonex®, Tysabri®, and Tecfidera®. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology.

Combined Therapeutics's Logo

Combined Therapeutics

Cambridge, United States

11-50 Employees

2016

Robert Langer is a Massachusetts Institute of Technology (MIT) professor and an expert in biotechnology and engineering. Dan Anderson is a Massachusetts Institute of Technology (MIT) professor and an expert in nano-based drugs and cancer immunology. Pierre Matussiere has more than twenty years of experience as an investment banker for Société Générale, Citigroup and BNP Paribas, primarily out of London. Kevin McLaughlin is a finance and management executive with more than 40 years of experience in the biopharma and high-tech industries. Robert Ruffolo is the former president of research & development at Wyeth Pharmaceuticals and brings a wealth of experience in drug discovery and development. Paul Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries.

Portage Biotech's Logo

Portage Biotech

Old Toronto, Canada

1-10 Employees

1973

Our Mission: To identify and accelerate promising medicines that revolutionize treatment and quality of life for patients with cancer. We know quality science and leverage our team’s deep knowledge to create a viable product development strategy that supports commercial potential and company growth. Among our most notable projects is the early investment, formation and growth of Biohaven Pharmaceuticals, leading the Company to the second-largest IPO in 2017 and later its successful commercialization leading to acquisition by Pfizer for approximately $12 billion in 2022. Each platform in our pipeline yields multiple products, and those products are discussed with potential big pharma partners and selected for clinical development if they are differentiated and have a compelling product profile. Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases. Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies. Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals , part of the Johnson & Johnson group of companies. Steve Innaimo is a seasoned R&D expert who brings more than 25 years of experience in drug development from the large pharma, biotech and contract research organization sectors.

Amolyt Pharma's Logo

Amolyt Pharma

Écully, France

11-50 Employees

2007

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations. Thierry Abribat is a biotech entrepreneur who has founded and managed three biotech companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics (Nasdaq: MLND). Mark Sumeray has 23 years of experience across the pharmaceutical, medical devices and biotech industries, both in the US and EU. Thomas Delale is a biopharmaceutical professional with over 18 years of experience that spans from peptide drug discovery to late clinical stage development and corporate/business development. David has a strong experience working with CMO/CRO and developing product with top pharmaceutical or biotechnologies companies in Europe, US, India and China. Benedicte Gagnere has over 20 years experience in leading financial planning, control & accounting functions and reporting on all international operations. Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma.